Myeloproliferative neoplasms
Conditions
Interventions
Trial group:An individualized treatment regimen primarily utilizing decitabine (10mg d1-5 days) is employed, combined with other targeted drugs selected based on gene mutation and transcriptome analys
Sponsors
The Second Medical Center of Chinese PLA General Hospital?
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients aged between 18 and 100 years old; 2.Diagnosed with advanced MPN according to WHO or IWG-MRT criteria, and exhibiting one of the following characteristics; 3. Bone marrow biopsy results indicate moderate to severe fibrosis (MF-2 or MF-3); 4. The genetic testing results indicate the presence of high-risk mutations (such as JAK2 V617F >50% burden, CALR type 2, MPL mutation, TP53, ASXL1, EZH2, etc.); 5.The clinical manifestations are severe splenomegaly or persistent hematological abnormalities (such as significant decrease in red blood cells or significant increase/decrease in platelets); 6. Acute leukemia with progression of MPN diagnosed; 7.Sign the informed consent form, expressing willingness to accept an individualized treatment regimen primarily consisting of decitabine.
Exclusion criteria
Exclusion criteria: 1. Patients with severe comorbidities or other systemic diseases, such as: Hepatic and renal failure: significant abnormalities in serum creatinine and liver function tests (ALT/AST); Severe cardiovascular diseases: such as uncontrolled hypertension, heart failure, or recent myocardial infarction. 2.Patients who have previously received incompatible treatments: Patients who have used other hypomethylating drugs (such as azacitidine) within the last 6 months; patients who have undergone extensive chemotherapy or radiotherapy and have severe bone marrow dysfunction; patients who are allergic to decitabine or other components of combination therapy; pregnant or lactating women, or women of childbearing age who are unwilling to use contraception.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of primitive cells;Changes in peripheral blood counts (red blood cells, white blood cells, and platelets); | — |
Secondary
| Measure | Time frame |
|---|---|
| Spleen size;Changes in transcriptome and gene mutation spectrum;Improvement in clinical symptoms, such as changes in body weight, physical condition, and incidence of fever and night sweats; | — |
Countries
China
Contacts
Public ContactYang Bo
The Second Medical Center of Chinese PLA General Hospital?
Outcome results
None listed